Treatment of Drug Susceptible Pulmonary Tuberculosis

• Published in: Tuberculosis and respiratory diseases Vol. 78; no. 3; pp. 161 - 167
• Main Authors: Shin, Hong-Joon, Kwon, Yong-Soo
• Format: Journal Article
• Language: English
• Published: Korea (South) The Korean Academy of Tuberculosis and Respiratory Diseases 01.07.2015; 대한결핵및호흡기학회
• Subjects: Review; 내과학; Fluoroquinolones; Tuberculosis; Antitubercular Agents; Combination Therapy; Drug-Related Side Effects and Adverse Reactions
• ISSN: 1738-3536; 2005-6184
• DOI: 10.4046/trd.2015.78.3.161

Tuberculosis (TB) remains a major global health problem, and the incidence of TB cases has not significantly decreased over the past decade in Korea. The standard short course regimen is highly effective against TB, but requires multiple TB-specific drugs and a long treatment duration. Recent studies using late-generation fluoroquinolones and/or high-dose rifapentine-containing regimens to shorten the duration of TB treatment showed negative results. Extending the treatment duration may be considered in patients with cavitation on the initial chest radiograph and positivity in sputum culture at 2 months of treatment for preventing TB relapse. Current evidence does not support the use of fixed-dose combinations compared to separate drugs for the purpose of improving treatment outcomes. All patients receiving TB treatment should be monitored regularly for response to therapy, facilitation of treatment completion, and management of adverse drug reactions. Mild adverse effects can be managed with symptomatic therapy and changing the timing of the drug administration, but severe adverse effects require a discontinuation of the offending drugs.